Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance

If you need an accessible version of this item, please submit a remediation request.
Date
2022-04
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
T&F
Abstract

Glioblastoma (GBM) is a deadly malignancy with a poor prognosis. An important factor contributing to GBM recurrence is high resistance of GBM cancer stem cells (GSCs). While temozolomide (TMZ), has been shown to consistently extend survival, GSCs grow resistant to TMZ through upregulation of DNA damage repair mechanisms and avoidance of apoptosis. Since a single-drug approach has failed to significantly alter prognosis in the past 15 years, unique approaches such as multidrug combination therapy together with distinctive targeted drug-delivery approaches against cancer stem cells are needed. In this review, a rationale for multidrug therapy using a targeted nanotechnology approach that preferentially target GSCs is proposed with discussion and examples of drugs, nanomedicine delivery systems, and targeting moieties.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Smiley, S. B., Zarrinmayeh, H., Das, S. K., Pollok, K. E., Vannier, M. W., & Veronesi, M. C. (2022). Novel Therapeutics and drug-delivery Approaches in the Modulation of Glioblastoma Stem Cell Resistance. Therapeutic Delivery, 13(4), 249–273. https://doi.org/10.4155/tde-2021-0086
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Therapeutic Delivery
Source
Publisher
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Full Text Available at
This item is under embargo {{howLong}}